Neonatal ventilation with inhaled nitric oxide vs. ventilatory support without inhaled nitric oxide for infants with severe respiratory failure born at or near term: The INNOVO multicentre randomised controlled trial

Neonatology

Volumn 91, Issue 2, 2007, Pages 73-82

  Field, D ^a,k   Elbourne, D ^b   Hardy, P ^b   Fenton, A C ^d   Ahluwalia, J ^e   Halliday, H L ^f   Subhedar, N ^g   Heinonen, K ^h   Aikio, O ⁱ   Grieve, R ^b   Truesdale, A ^b   Tomlin, K ^b   Normand, C ^j   Stocks, J ^c  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d ROYAL VICTORIA INFIRMARY   (United Kingdom)

^e Rosie Maternity Hospital   (United Kingdom)

^f ROYAL MATERNITY HOSPITAL   (United Kingdom)

^g LIVERPOOL WOMEN S HOSPITAL   (United Kingdom)

^h KUOPIO UNIVERSITY HOSPITAL   (Finland)

ⁱ UNIVERSITY OF OULU   (Finland)

^j TRINITY COLLEGE DUBLIN   (Ireland)

^k LEICESTER ROYAL INFIRMARY   (United Kingdom)

more..

Author keywords

Neonatal intensive care; Nitric oxide; Respiratory failure; Term infants; Ventilation

Indexed keywords

NITRIC OXIDE;

ARTICLE; ARTIFICIAL VENTILATION; BELGIUM; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEATH; DISABILITY; EXTRACORPOREAL OXYGENATION; FEMALE; FINLAND; FISHER EXACT TEST; HEALTH CARE COST; HOSPITALIZATION COST; HUMAN; IRELAND; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEWBORN; PREGNANCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; RISK FACTOR; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVOR; UNITED KINGDOM;

ADMINISTRATION, INHALATION; BRONCHODILATOR AGENTS; COST-BENEFIT ANALYSIS; FEMALE; GESTATIONAL AGE; HOSPITALIZATION; HUMANS; INFANT, NEWBORN; INTENSIVE CARE, NEONATAL; MALE; NITRIC OXIDE; RESPIRATION, ARTIFICIAL; RESPIRATORY DISTRESS SYNDROME, NEWBORN; SURVIVAL RATE; TERM BIRTH; TREATMENT OUTCOME;

EID: 33847070744     PISSN: 16617800     EISSN: 16617819     Source Type: Journal    
DOI: 10.1159/000097123     Document Type: Article

References (18)

1. Finer NN, Barrington KJ: Nitric oxide for respiratory failure in infants born at or near term (Cochrane Review); in The Cochrane Library, Issue 1, Chichester, UK, John Wiley & Sons, Ltd., 2004 (last updated 07 June 2001).
2. UK Collaborative ECMO Trial Group: UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation. Lancet 1996;348:75-82.
3. Bennett CC, Johnson A, Field D, Elbourne D, for the UK Collaborative ECMO Group: The UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation: follow-up to age 4 years. Lancet 2001;257:1094-1096.
4. Neonatal Inhaled Nitric Oxide Study Group: Inhaled nitric oxide in full-term and nearly full term infants with hypoxic respiratory failure. N Engl J Med 1997;336:597-604.
5. Clark RH, et al: Low dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. N Engl J Med 2000;342:469-474.
6. Neonatal Inhaled Nitric Oxide Study Group: Inhaled nitric oxide in term and near-term infants: Neurodevelopmental follow-up of the Neonatal Inhaled Nitric Oxide Study Group (NINOS). J Pediatr 2000;136:611-617.
7. Jacobs P, Finer NN, Fassbender K, Hall E, Robertson CM: Cost-effectiveness of inhaled nitric oxide in near-term and term infants with respiratory failure: eighteen- to 24-month follow-up for Canadian patients. Crit Care Med 2002;30:2330-2334.
8. Field D, Elbourne D; Truesdale A, Grieve R, Hardy P, Fenton A, et al, on behalf of the INNOVO Trial Collaborating Group: Neonatal ventilation with Inhaled Nitric Oxide versus Ventilatory support without inhaled nitric oxide for preterm infants with severe respiratory failure: The INNOVO multicentre randomised controlled trial (ISRCTN 17821339). Pediatrics 2005;115:926-936.
9. Pan H, Goldstein H, Rasbash J: LGROW: a system for longitudinal growth norms version 2.0. 1998.
10. Department of Health: Reference Costs 2002. National Schedule of Reference Costs. Leeds, Department of Health, 2002.
11. Roberts TE, the ECMO Economics working Group on behalf of the ECMO trial steering group: Economic evaluation and randomised controlled trial of extracorporeal membrane oxygenation: UK collaborative trial. BMJ 1998;317:911-916.
12. NHS Executive: Hospital and Community Health Services (HCHS) Pay and Price Index. Leeds, 2002.
13. SAS Institute Inc.: SAS System for Windows. Version 8.02. Cary, N.C., USA. 1999-2001.
14. Haybittle JL: Repeated assessment of results in clinical trials of cancer treatment. Br J Radiol 1971;44:793-797.
15. Angus DC, Clermont G, Watson RS, Linde-Zwirble WT, Clark RH, Roberts MS: Cost-effectiveness of inhaled nitric oxide in the treatment of neonatal respiratory failure in the United States. Pediatrics 2003;112:1351-1360.
16. Field D, Normand C, Elbourne D: Cost-effectiveness of inhaled nitric oxide in the treatment of neonatal respiratory failure in the US. Pediatrics, Commentary 2003;112:1422-1423.
17. Thompson SG, Barber JA: How should cost data in pragmatic trials be analysed? BMJ 2000;320:1197-2000.
18. OECD: Main Economic Indicators. Paris, France: OECD, 2004.